FIBROGEN INC - COMMON

FibroGen to Report Third Quarter 2021 Financial Results

26 окт 2021 04:00:00 Источник Nasdaq GlobeNewswire

FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021

25 окт 2021 04:00:01 Источник Nasdaq GlobeNewswire

FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

25 авг 2021 04:00:00 Источник Nasdaq GlobeNewswire

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

19 авг 2021 16:35:00 Источник Nasdaq GlobeNewswire

FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer

16 авг 2021 04:00:01 Источник Nasdaq GlobeNewswire

FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease

11 авг 2021 04:00:01 Источник Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2021 Financial Results

09 авг 2021 13:01:00 Источник Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2021 Financial Results

29 июл 2021 04:00:01 Источник Nasdaq GlobeNewswire

Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform

19 июл 2021 04:00:00 Источник Nasdaq GlobeNewswire

FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

15 июл 2021 15:26:31 Источник Nasdaq GlobeNewswire

FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

12 июл 2021 04:00:00 Источник Nasdaq GlobeNewswire

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

25 июн 2021 06:15:00 Источник Nasdaq GlobeNewswire

FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease

17 июн 2021 04:00:00 Источник Nasdaq GlobeNewswire

Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform

16 июн 2021 05:00:01 Источник Nasdaq GlobeNewswire

FibroGen to Present at Upcoming Investor Conferences

27 май 2021 04:00:00 Источник Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2021 Financial Results

10 май 2021 13:01:00 Источник Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2021 Financial Results

03 май 2021 04:00:00 Источник Nasdaq GlobeNewswire

FibroGen to Present at Upcoming Investor Conference

28 апр 2021 04:00:00 Источник Nasdaq GlobeNewswire

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

15 апр 2021 04:00:00 Источник Nasdaq GlobeNewswire

FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

12 апр 2021 04:00:01 Источник Nasdaq GlobeNewswire